Tag: nature

Posts with tag: nature

Latest Posts

Trump 2.0's Rocky Start: M&A Slowdown, Political Heat, and Regulatory Uncertainties

January brings surprises as Wall Street adjusts to Trump 2.0, with slower dealmaking and political pressure on big banks.

Fed Chair Powell: No Rush to Adjust Rates Despite Stubborn Inflation and Trump Uncertainty

Fed Chair Powell says interest rates likely not going up anytime soon, citing strong economy, inflation pressures

Super Micro Computer Stock Falls 5% After 5-Day Rally

Shares of Super Micro Computer (SMCI) plunged over 5% Tuesday after a 5-day rally. Learn about the company's challenges and upcoming earnings report.

GDS Mulls $500 Million IPO for Offshore Unit

Chinese data center operator GDS Holdings considers a US IPO of its international arm, DayOne, aiming to raise around $500m.

Vertiv (VRT) Q4 Earnings Preview: What Analysts Expect

Vertiv (VRT) Q4 Earnings Preview: Revenue Growth, Earnings Expectations, and Stock Price Analysis

Paycom Earnings Preview: What to Expect

Paycom (PAYC) reports earnings tomorrow. Analysts expect revenue to grow 10.7% to $481.2 million, with adjusted earnings per share of $1.97. Read more to see what to expect and why the HR software sector is seeing positive sentiment.

AppLovin Reports Earnings Tomorrow: Analyst Expectations and Market Trends

AppLovin (APP) is set to report earnings tomorrow after the market closes. Analysts expect revenue to grow 32.5% to $1.26 billion, with adjusted earnings of $1.79 per share. Read our analysis for what to expect.

Tenet Healthcare (THC) Q4 Earnings Preview: Revenue Decline Expected

Tenet Healthcare (THC) reports Q4 earnings tomorrow. Analysts expect revenue to decline 3.8% to $5.17 billion, with adjusted EPS of $2.83. Read our full analysis for insights and predictions.

QuidelOrtho Earnings Preview

QuidelOrtho (QDEL) earnings preview: Revenue expected to decline 6% YoY to $698.4 million, with adjusted earnings of $0.58 per share. Analysts have reconfirmed estimates, and QuidelOrtho has historically exceeded revenue expectations by 6.6% on average.

ESSA Pharma Reports Fiscal Q1 Loss of $8.5 Million

ESSA Pharma Inc. (EPIX) reports a Q1 loss of $8.5 million, or 19 cents per share.